胃癌与辅助放化疗：何时何地进行，这才是问题所在。
Gastric cancer and adjuvant chemoradiotherapy: when and where, that's the question.
作者信息
Kantzou I, Sarris G, Poulizi M, Zygogianni A, Liakakos T, Kouvaris J, Bountouroglou N, Kouloulias V
机构信息
Kapodistrian University of Athens, 2nd Department of Radiology, Athens, Greece.
出版信息
J BUON. 2011 Jul-Sep;16(3):473-7.
PURPOSE
Although the incidence of gastric cancer is decreasing, there were still 159,900 new cases and 118,200 deaths in Europe in 2006 representing the 5th highest incidence and 4th highest cause of cancer-related deaths. Postoperative adjuvant chemoradiotherapy has been demonstrated to result in a significant improvement in overall and disease-free survival. We studied the current role of adjuvant chemoradiotherapy in gastric cancer.
METHODS
Randomized phase III studies and selected phase II studies for adjuvant chemoradiotherapy in gastric cancer were searched in PUBMED using key words. Also, international treatment guidelines as well as review papers were searched and analysed.
RESULTS
Based on the published literature, treatment guidelines and reports from international meetings it is obvious that adjuvant chemoradiotherapy in gastric cancer contributes in improved treatment results.
CONCLUSION
Surgical resection remains the cornerstone of curative treatment for gastric cancer. The combination of modern radiotherapy techniques with chemotherapy is feasible, safe and improves overall survival of patients with gastric cancer.
目的
尽管胃癌的发病率在下降，但2006年欧洲仍有159,900例新发病例和118,200例死亡病例，其发病率位居第五，癌症相关死亡原因位居第四。术后辅助放化疗已被证明能显著提高总生存率和无病生存率。我们研究了辅助放化疗在胃癌中的当前作用。
方法
在PUBMED中使用关键词搜索胃癌辅助放化疗的随机III期研究和选定的II期研究。此外，还搜索并分析了国际治疗指南以及综述文章。
结果
根据已发表的文献、治疗指南和国际会议报告，很明显胃癌辅助放化疗有助于改善治疗效果。
结论
手术切除仍然是胃癌根治性治疗的基石。现代放疗技术与化疗相结合是可行、安全的，并且能提高胃癌患者的总生存率。
Zotero 插件